Spruce Biosciences, Inc. (SPRB)

Market Cap	30.63M
Revenue (ttm)	10.09M
Net Income (ttm)	-47.92M
Shares Out	41.15M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	502,723
Open	0.755
Previous Close	0.742
Day's Range	0.733 - 0.757
52-Week Range	0.671 - 5.950
Beta	2.53
Analysts	Hold
Price Target	3.60 (+383.61%)
Earnings Date	May 13, 2024

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB

Analyst Forecast

According to 8 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $3.6, which is an increase of 383.61% from the latest price.

Price Target

$3.6

(383.61% upside)

Analyst Consensus: Hold